Stock A069620 DAEWOONG PHARMACEUTICAL CO., LTD
Add to a list
To use this feature you must be a member
Log inSign up

All News Daewoong Pharmaceutical Co., Ltd

Equities

A069620

KR7069620003

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-20 EDT 		5-day change 1st Jan Change
110,600 KRW -0.72% Intraday chart for Daewoong Pharmaceutical Co., Ltd +0.82% -5.31%
04-24 Korean Sugar Imports Plunge 14% as Diabetes Cases Surge MT
04-12 AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Korean Sugar Imports Plunge 14% as Diabetes Cases Surge
MT
AEON Biopharma, Inc. announced that it has received $15 million in funding from Daewoong Pharmaceutical Co., Ltd
CI
AEON Biopharma, Inc. announced that it expects to receive $15 million in funding from Daewoong Pharmaceutical Co., Ltd
CI
Daewoong Pharmaceutical Secures Approval for Stem Cell Processing Facility in Indonesia
MT
Daewoong Pharmaceutical : and Zydus Announce Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S.
PU
Zydus Worldwide DMCC and Daewoong Pharmaceutical Co., Ltd. Announces Exclusive Licensing Agreement for Development and Commercialization of Leuprolide Long-Acting Injectable in the U.S
CI
Daewoong Pharmaceutical : Strikes a $60 Million Deal with JSC Pharmasyntez for Diabetes Novel Drug Enavogliflozin
PU
Daewoong Pharmaceutical Received GMP Certification from Brazilian ANVISA
AQ
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative GLP-1 Obesity Treatment with Advanced Microneedle Technology for Sustained Weekly Efficacy
CI
P.T. Selatox Bio Pharma announced that it expects to receive IDR 200 billion in funding from Daewoong Pharmaceutical Co., Ltd
CI
Daewoong Pharmaceutical : announces ‘3E Global Hyper-Competitive Strategy' at CPHI 2023... Aiming for USD 745M in novel drug sales by 2030
PU
Daewoong Pharmaceutical to Participates in CPHI Worldwide 2023, Showcasing Own Novel Drug in the Global Market
AQ
Daewoong Therapeutics Gets Mfds Nod for Phase 1 Ind for the World's First Eyedrop Treatment for Diabetic Retinopathy and Macular Edema
CI
Hyphens Pharma Unit to Distribute Daewoong Pharmaceutical's Nabota Botox in Malaysia
MT
Hyphens Pharma International Limited Announces Successful Registration in Malaysia
CI
Daewoong Pharmaceutical : Initiates Global Export of 'Novel Drug'...Launches 'Fexuprazan' in the Philippines
PU
Daewoong pharmaceutical Co.,Ltd Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Daewoong Pharmaceutical's Nabota Surpasses 600,000 Customers in the US
MT
Daewoong Pharmaceutical : Reports Second Quarter 2023 Financial Results
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A069620 Stock
  4. News Daewoong Pharmaceutical Co., Ltd
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW